01—Abstract
Summary
Summary of the 10-Q filed November 5, 2024. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Inc. reported solid third-quarter 2024 results, driven by strong performance in its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO, which saw a 14%a increase in revenue year-over-year.
Overall product revenues grew 12% to $2.8 billionb. Despite this revenue growth, the company reported a net loss of $1.45 billion for the first nine months of 2024, primarily due to a significant $4.4 billion acquired in-process research and development (AIPR&D) expense related to the acquisition of Alpine Immune Sciences, Inc. in May 2024. This acquisition, while substantial, brings a promising candidate, povetacicept, for IgA nephropathy.
The company is also advancing its pipeline with key near-term launch opportunities including vanzacaftor/tezacaftor/deutivacaftor for CF (PDUFA date January 2, 2025) and suzetrigine for acute pain (PDUFA date January 30, 2025). Furthermore, Vertex continues to invest heavily in research and development, with expenses for the first nine months of 2024 totaling $2.6 billionc, reflecting its commitment to its diverse pipeline across various therapeutic areas beyond CF.
02—Key points
Key Highlights
- Product revenues increased 12% to $2.8 billion in Q3 2024, with TRIKAFTA/KAFTRIO revenues up 14% year-over-year, indicating strong demand for its cystic fibrosis treatments.
- The company reported a net loss of $1.45 billion for the first nine months of 2024, significantly impacted by a $4.4 billion AIPR&D expense from the acquisition of Alpine Immune Sciences, Inc.
- Significant progress is being made on near-term product launches: vanzacaftor/tezacaftor/deutivacaftor for CF has a PDUFA date of January 2, 2025, and suzetrigine for acute pain has a PDUFA date of January 30, 2025.
- Research and development expenses increased by 13% to $2.6 billion for the first nine months of 2024, demonstrating continued investment in pipeline development across multiple therapeutic areas.
- Cash, cash equivalents, and marketable securities decreased by 18% to $11.2 billion as of September 30, 2024, largely due to the $5.0 billion cash payment for the Alpine acquisition.
- CASGEVY, a gene-edited therapy for sickle cell disease and beta thalassemia, received approvals in Switzerland and Canada, with ongoing reimbursement discussions and early access programs being implemented.
- The company repurchased $759.2 million of its common stock in the first nine months of 2024, with $1.8 billion remaining authorization under its share repurchase program.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Vertex Pharmaceuticals Inc kept $0.38.
- Revenue$2.77B100.0%
- Cost of revenue−$392.6M14.2%
- Gross profit$2.38B85.8%
- Operating costs−$1.26B45.6%
- Operating income$1.12B40.3%
- Interest, other & tax−$70.9M2.6%
- Net income$1.05B37.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 5, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $2.77B$2.48B | +11.6% |
| Cost of Revenue | $392.60M$318.70M | +23.2% |
| Gross Profit | $2.38B$2.16B | +9.9% |
| SG&A Expenses | $371.80M$263.80M | +40.9% |
| Operating Expenses | $1.66B$1.45B | +14.5% |
| Operating Income | $1.12B$1.04B | +7.5% |
| Net Income | $1.05B$1.04B | +1.0% |
| EPS (Basic) | $4.05$4.01 | +1.0% |
| EPS (Diluted) | $4.01$3.97 | +1.0% |
| Shares Outstanding (Basic) | 258.00M258.00M | 0.0% |
| Shares Outstanding (Diluted) | 261.00M260.60M | +0.2% |
05—Questions
Frequently Asked Questions
What was the primary driver of Vertex's net loss in the first nine months of 2024?
The primary driver of Vertex's net loss of $1.45 billion for the first nine months of 2024 was a substantial acquired in-process research and development (AIPR&D) expense of $4.4 billion related to the asset acquisition of Alpine Immune Sciences, Inc. in May 2024.
How is the company managing its cash position after the Alpine acquisition?
Following the $5.0 billion cash acquisition of Alpine, Vertex's total cash, cash equivalents, and marketable securities decreased by 18% to $11.2 billion as of September 30, 2024. The company expects its existing cash and cash flows from product sales to be sufficient for operations for at least the next twelve months.
What are the key upcoming catalysts for Vertex Pharmaceuticals?
Key upcoming catalysts include the potential FDA approval of vanzacaftor/tezacaftor/deutivacaftor for cystic fibrosis with a PDUFA date of January 2, 2025, and suzetrigine for acute pain with a PDUFA date of January 30, 2025. The company is also advancing its diverse pipeline with numerous clinical-stage programs.
What is the outlook for Vertex's cystic fibrosis business?
Vertex anticipates continued growth in its CF business through label expansions (including younger age groups and rare mutations), ongoing uptake in younger patient populations, and an increasing number of people living with CF. The company is also developing mRNA and genetic therapies for patients who do not benefit from current CFTR modulators.
06—Continue